Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cue Biopharma Inc CUE

Healthcare Biotechnology
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease... see more

Recent & Breaking News (NDAQ:CUE)

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 10 days ago

Cue Biopharma Announces Strategic Organizational Transition

GlobeNewswire 10 days ago

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

GlobeNewswire 12 days ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

GlobeNewswire November 8, 2024

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

GlobeNewswire October 4, 2024

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

GlobeNewswire September 26, 2024

Cue Biopharma Announces Proposed Public Offering

GlobeNewswire September 26, 2024

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

GlobeNewswire September 9, 2024

Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference

GlobeNewswire September 3, 2024

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire August 19, 2024

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire August 13, 2024

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

GlobeNewswire July 25, 2024

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

GlobeNewswire June 4, 2024

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024

GlobeNewswire June 3, 2024

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire May 9, 2024

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

GlobeNewswire May 8, 2024

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

GlobeNewswire May 7, 2024

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 24, 2024

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

GlobeNewswire April 8, 2024

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire April 2, 2024